You Joined a Genomics Study. What Must You Disclose?

Taking part in a genomics research study — the 100,000 Genomes Project, say, or another Genomics England programme — does not create anything you have to disclose to a life insurer. Participation itself is not something a UK life insurance application asks about, and any genetic result generated in the course of research is protected. You did not sign away your insurance position by joining a study.

The part that does need care is what happens afterwards. A research finding stays outside the insurer's reach, but if it is confirmed by NHS testing, or leads to monitoring, medication or surgery, that clinical care becomes ordinary medical history — and ordinary medical history is disclosable wherever the application asks about it. The line to hold in your head is simple: disclosure follows clinical care, not research participation.

That distinction is not something you have to work out for yourself. It is set out in guidance Genomics England developed together with the Association of British Insurers, precisely so participants know where they stand before they consent to take part.

The short answer: participation is not disclosable, clinical care is

A research study is not part of your medical record in the way a GP consultation is. When you join a project like the 100,000 Genomes Project, your samples are analysed for research, and the arrangements are built so that what happens inside the study stays inside it as far as insurance is concerned. An insurer cannot ask whether you took part, and cannot ask for a result the study produced.

What an insurer does ask about is your health: your diagnoses, your symptoms, your treatment, your investigations. If nothing in your actual medical care changed because of the study, there is nothing new to declare. If something did change — a hospital referral, a scan, a course of tablets, an operation — then that care is disclosable, in the same way it would be if it had arisen any other way. The study is not the disclosable thing; the clinical consequence, if there is one, is.

This holds true even when the study is a large, well-known one attached to the NHS. People sometimes assume that because a genomics programme runs through NHS hospitals, anything it finds automatically lands in their medical record and becomes fair game for an insurer. It does not work that way. The research analysis and your clinical record are kept as separate strands, and it is only when a finding is deliberately moved from the research side into your NHS care that it starts to matter for disclosure.

What makes a result a research result

The protection turns on the setting in which a result was produced. A result generated for research — as part of a study's own analysis, under its consent and governance — is a research result, and research results are not disclosable to insurers. This is a broad protection, broader in some ways than the general rule for predictive tests, because a research result sits outside the insurance process entirely.

A clinical test is different. If, prompted by the study or otherwise, the NHS runs a test on you as part of your care — to confirm a finding, to diagnose a condition, to guide treatment — that is a clinical test, and its status is the ordinary one. A predictive clinical result still cannot be asked for on a life application, but a diagnosis and the treatment around it are medical history. The key is not the topic but the setting: research, or care.

This is why a validated finding matters more than a raw research signal. Research analyses can throw up uncertain or unconfirmed signals that mean little on their own. It is when a finding is taken into your clinical care and acted on that it starts to generate the kind of medical record an insurer asks about.

What the Code and the Genomics England guidance say

The underlying rule is in the Code on Genetic Testing and Insurance published by the Association of British Insurers, the voluntary agreement between the insurance industry and government. It commits insurers not to ask for or use predictive genetic results, and it treats results obtained through research as not disclosable at all.

Source: HM Government and Association of British Insurers, Code on Genetic Testing and Insurance.

Genomics England, which runs England's large-scale genomic programmes, produced participant guidance in step with the ABI that says the same thing in plain terms: taking part will not affect your ability to get insurance, and you do not have to tell an insurer about research participation or research results. That alignment between the research body and the insurers is the point — it is not two organisations offering different reassurances, but one agreed position.

It is worth being precise about what that guidance is, and is not. It is not a promise that no consequence can ever reach an insurer, because clinical care that follows a study plainly can. What it settles is the narrower and more useful question people actually ask before they consent: does joining, in and of itself, hand the insurer anything? The answer is no. You keep exactly the insurance position you had before you took part, and the study cannot be used as a back door to a result the insurer would otherwise be barred from seeing.

There is a single narrow exception in the Code, and it is worth knowing simply so you can see that it does not reach you here: a Huntington's disease result may be asked about, but only where total life cover exceeds £500,000, and only as a clinical predictive result rather than a research one. For research findings, and for every other condition, the protection holds.

The line that matters: disclosure follows clinical care

If you take one thing from this, take the boundary. Joining a study, and any result the study generates, is on the protected side. Clinical care that happens in the real world of your NHS record is on the disclosable side. The study can lead to the second, but the two do not merge.

So a finding that is confirmed by an NHS test, a condition that gets diagnosed, a medication you are started on, a surveillance programme you are entered into, or surgery you undergo — all of that is ordinary medical history and is disclosable if the application asks about it. A clinical follow-up test that is itself a predictive genetic test remains protected as a result, but the appointments, diagnoses and treatment surrounding it do not. The same logic runs through related situations: an echocardiogram showing hypertrophic cardiomyopathy is not a genetic test, so any finding on it is disclosable clinical evidence even though a gene test done alongside would be protected.

If the study offers to feed a result back to you

Some genomics studies offer participants the chance to receive certain findings — often called feedback of actionable results — where something clinically important and treatable has turned up. Being offered this, and choosing to receive it, does not by itself create a disclosure. The feedback is still a research communication about a research result, and a research result is protected.

What changes the position is what you do next. In almost every case, a fed-back result that matters is confirmed through NHS clinical testing before anyone acts on it, and you are then brought into ordinary NHS care — reviewed in a clinic, monitored, perhaps treated. From that point the confirmed diagnosis and the care around it are part of your medical record and are disclosable if asked. So the moment of disclosure is not when the study emails you; it is when your NHS care picks the finding up and does something with it.

This is a fine but important line, and it is the same one that catches people in related settings. A relative's discovery that sends you for your own clinical testing, for instance, changes the status of your test even though it began in research — the family-history questions and the research exemption do not always travel together. The safe habit is to answer honestly about the clinical care you have actually received, and to leave the research result itself alone, because the insurer cannot ask for it.

What a life application actually asks you

It helps to remember how narrow and specific the questions on a life application are. You are asked about your own health and, within limits, your family's — not about research you have volunteered for. The family history questions in particular are tightly bounded: they cover a defined set of conditions and, generally, only your closest relatives.

Because your GP holds no records for your relatives, a report from your own doctor can only repeat what you yourself told the practice, a boundary we set out in what your GP can actually tell a life insurer. Which relatives even count is narrower than people assume, as the first-degree rule for half-siblings and step-parents explains. And the general shape of what an underwriter treats as disclosable, versus what a strong-sounding family story actually contains, is worked through for the cardiac side in a family history of heart attacks across two generations. None of these questions asks you to reveal a study you joined.

Across the UK, and why the protection is broad

The insurance rules are UK-wide. The Code on Genetic Testing and Insurance and the duty to take reasonable care apply the same way in England, Scotland, Wales and Northern Ireland, so the protection for research participation does not change with where you live. What differs is the research and genomic-medicine machinery itself: Genomics England's programmes are delivered through the NHS in England, while Scotland, Wales and Northern Ireland run their own genomic-medicine arrangements. That affects how you take part, not what an insurer may ask.

The protection is drawn deliberately wide because public benefit depends on it. Research studies only work if enough people join, and the concern that participation might rebound on insurance is a known deterrent — a 2025 review of the Code noted exactly that worry about testing generally. Making research results non-disclosable removes the reason to hesitate. The practical takeaway is that joining a study changes nothing about your insurance position by itself; only clinical care can do that. Some inherited conditions are best understood by whether you are actually affected rather than merely flagged, as with haemochromatosis, where carrier or affected changes everything — the same care over what a result really means applies to anything a study turns up.

If you are thinking about putting cover in place, whether or not you are in a study, you can get life insurance quotes and have an FCA-authorised broker assess your application on your actual medical history. The related questions on inherited risk are gathered in our guide to family history, inherited risk and the odds.

Frequently asked questions

Do I have to tell an insurer I took part in a genomics study?

No. Results generated in research are not disclosable under the Code on Genetic Testing and Insurance, and Genomics England guidance developed with the Association of British Insurers says the same. Participation itself is not something a UK life insurance application asks you about.

What if the study found something?

The research result stays protected, but what happens next may not. If a finding is confirmed by NHS testing, or leads to monitoring, medication or surgery, that clinical care becomes ordinary medical history and must be disclosed wherever the application asks about it.

Does this put people off joining studies?

It is a common worry, and the 2025 review of the Code noted insurance fears deterring testing. The protection for research findings is deliberately broad for that reason. The point to grasp is that disclosure follows clinical care, not participation, so joining a study changes nothing by itself.